Aegirbio AB is pleased to announce that its abstract entitled “Use of Non-Invasive Saliva Samples to Determine Serum Concentrations of Biologic Drugs.” has been accepted for poster presentation at the upcoming ACTRIMS forum to be held in San Diego this February 23rd through 25th. The ACTRIMS forum is the largest gathering of neurologists and scientists focused on Multiple Sclerosis (MS) in the US and often showcases cutting edge research in the field complementary to work presented at ECTRIMS. The company’s poster presentation will show the results from our clinical study comparing saliva to blood based TDM.

“Our investments in saliva-based testing are beginning to produce returns in the form of groundbreaking, real world studies indicating that this approach is feasible and scientifically sound. Noninvasive sampling can potentially make therapeutic drug and immune monitoring much more accessible and easier to implement into clinical practice”. – Bradley Messmer, CEO

This press release will only be published in English.

Om AegirBio

AegirBio är ett svenskt diagnostikföretag som grundades 2019 för att offra tester för att övervaka och optimera doseringen av biologiska läkemedel via dess unika patenterade teknikplattform. I juni 2020 noterades AegirBio på NASDAQ First North Growth Market. Företagets ambition är, förutom att föra innovativ diagnostisk teknik till marknaden, för att göra diagnostik mer tillgänglig, enklare att använda och ge exakta och enkla överförbara resultat.

Related link:
Cision